Niraparib restrains prostate cancer cell proliferation and metastasis and tumor growth in mice by regulating the lncRNA MEG3/miR-181-5p/GATA6 pathway

Background Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi), have gained approval for treating patients with castration-resistant prostate cancer (CRPC). Maternally expressed gene 3 (MEG3), a long non-coding RNA (lncRNA), plays a role in inhibiting tumorigenesis through regulating DNA repair genes. This study aimed to investigate the association between the anti-prostate cancer (PCa) effect of niraparib, a representative PARPi, and MEG3 expression, as well as explore the downstream pathway involved. Methods The levels of MEG3, miR-181-5p, GATA binding protein 6 (GATA6) in clinical samples from PCa patients were accessed by RT-qPCR. PC3 cells were treated with niraparib, and the expression of MEG3, miR-181-5p, GATA6 expression was tested. PC3 cell proliferation, migration, and invasion were tested by CCK-8, wound healing, and Transwell assays, respectively. The bindings between miR-181-5p and MEG3/GATA6 were determined by dual-luciferase reporter gene assay. Furthermore, rescue experiments were conducted to investigate the underlying mechanism of MEG3/miR-181-5p/GATA6 axis in PCa progression. Additionally, mice were injected with PC3 cells transfected with sh-MEG3 and treated with niraparib, and the xenograft tumor growth was observed. Results MEG3 and GATA6 were upregulated and miR-181-5p was downregulated in PCa patients. Niraparib treatment substantially upregulated MEG3 and GATA6, and downregulated miR-181-5p expression in PCa cells. Niraparib effectively restrained PC3 cell proliferation, migration, and invasion. MiR-181-5p targeted to MEG3, and the inhibitory effects of MEG3 overexpression on PC3 cell proliferation and metastasis were abrogated by miR-181-5p overexpression. Moreover, GATA6 was identified as a target of miR-181-5p, and GATA6 silencing abolished the inhibitory effects of miR-181-5p inhibition on PC3 cell proliferation and metastasis. Besides, MEG3 silencing could abrogate niraparib-mediated tumor growth inhibition in mice. Conclusions Niraparib restrains prostate cancer cell proliferation and metastasis and tumor growth in mice by regulating the lncRNA MEG3/miR-181-5p/GATA6 pathway.


INTRODUCTION
Prostate cancer (PCa) is the second most common lethal cancer and ranks second in terms of mortality in males worldwide (Gandaglia et al., 2021).The aging population has significantly contributed to a sharp increase in the incidence and mortality of PCa.According to the 2023 cancer statistics, PCa incidence is increasing by 3% every year, which is equivalent to 99,000 new cases annually (Siegel et al., 2023).Traditional treatments like survey and radiation therapy have great limitations for PCa patients, with many succumbing to the disease or developing metastasis.Surgical treatment has high risk of complications, impacting patient's quality of life and carrying a potential for recurrence and distant metastasis.Meanwhile, radiation therapy has a biochemical recurrence rate of approximately 40% and may cause side effects such as frequent urination and urgency.Moreover, it may not be effective for advanced PCa.The presence of metastatic PCa has been linked with an increased risk of mortality, contributing to 13% of all cancer-related deaths and significantly impacting patients' survival and life quality (Bartzatt, 2020).At present, the primary therapy for PCa is androgen deprivation (ADT) therapy, which can suppress tumor growth and delay clinical tumor progression (Achard et al., 2022).However, the emergence of ADT resistance in PCa patients drives the disease to the castration resistant prostate cancer (CRPC) stage (Teo, Rathkopf & Kantoff, 2019;Arora & Barbieri, 2018).Currently, continuous in-depth studies have developed various new drugs for CRPC.Nonetheless, this poses a major clinical challenge, including the selection of tailored for individual patients, the optimal combination of these new effective drugs, and an exploration of the mechanisms underlying acquired resistance (Norz & Rausch, 2021).
Drugs targeting poly (ADP-ribose) polymerase (PARP) to regulate cell proliferation and metastasis have gradually been applied in the clinical treatment of PCa (Risdon et al., 2021).PARP inhibitors (PARPi) exert their effects through synthetic lethality of homologous recombination repair gene defects, such as BRAC, inhibiting DNA damage repair and promoting apoptosis in cancer cells (Slade, 2020;Li et al., 2020).PARPi inhibit the catalytic activity of PARP1 by competitively binding to its catalytic domain, preventing the repair of single-strand, and converting them to double-strand breaks.If cancer cells have homologous recombination (HR) repair gene defects, DNA damage cannot be repaired, leading to cancer cell apoptosis (D'Andrea, 2018).Moreover, PARPi enhance the binding strength between PARP1 and damaged DNA, inducing PARP1 trapping, which blocks the potential DNA repair pathway and ultimately kills cancer cells (D'Andrea, 2018).As HR repair genes are essential for DNA repair pathways, PARPi can selectively kill cells with HR repair gene defects (Li et al., 2020).PARPi have been approved for the treatment of breast and ovarian cancer (Cortesi, Rugo & Jackisch, 2021;Mittica et al., 2018).Olaparib and talazoparib have already been approved by the United States Food and Drug Administration (FDA) for the treatment of BRCA-mutated breast cancer based on positive outcomes in phase 3 trials (Cortesi, Rugo & Jackisch, 2021).Niraparib treatment has shown significantly longer progression-free survival in patients with advanced ovarian cancer compared to placebo treatment (González-Martín et al., 2019).The application of PARPi has also been expanded to treat advanced PCa.Olaparib treatment has been shown to improve the overall survival rate of metastatic CRPC (mCRPC) patients with HR repair defects by promoting DNA damage-induced cell death and suppressing tumor growth (Teyssonneau et al., 2021).Subsequent research has further confirmed that CRPC patients with multiple DNA HR repair gene defects can also benefit from PARPi, with a comprehensive response rate of 46.7% (Mateo et al., 2020).In particular, niraparib and talazoparib have shown impressive performance in phase II trials for mCRPC patients (Flippot et al., 2022).Furthermore, niraparib treatment has improved the objective response rate and progression-free survival in patients with biallelic BRCA1/2 alterations (Tripathi, Balakrishna & Agarwal, 2020).Recently, the FDA approved the fixed-dose combination of niraparib and abiraterone acetate for adult mCRPC patients with deleterious or suspected deleterious BRCA1/2 mutations (Bischoff & Barthélémy, 2023).Although numerous biomarkers, such as BRCA mutations and other genetic mutations related to HR, have been explored.However, there are still no gold standards for determining patients who are suitable candidates for PARPi therapy.Given the significant efficacy of niraparib in mCRPC treatment, studying its related regulatory mechanisms is of great significance.It is widely recognized that the regulatory mechanisms of PARPi mainly focus on DNA genetic variations and protein expression-mediated proliferation and apoptosis.However, it is not clear whether PARPi exerts antitumor effects through the regulation of the transcriptome level.To create more precise prognostic and therapeutic indicators and identify suitable candidates for PARPi use among the patient population, we need to consider the complex interactions among various genes and proteins in the underlying mechanisms.
Multiple abnormally expressed long non-coding RNAs (lncRNAs) play crucial roles in PCa development, and have been identified as promising therapeutic targets (Mirzaei et al., 2022).LncRNAs can serve as prognostic and diagnostic markers in clinical settings (Goyal et al., 2021).Moreover, lncRNAs regulate drug resistance and immune evasion in PCa cells (Zhang et al., 2022).Notably, microarray and RNA sequencing technologies have identified numerous predictive lncRNAs involved in biological pathways, including ADT therapy and PARP inhibition (Spratt, 2019).However, it is still unclear whether lncRNAs play a role in PARPi-mediated anti-PCa effects.Evidence suggests that the lncRNA maternally expressed gene 3 (MEG3) is downregulated in PCa tissues and cells, and overexpression of MEG3 can attenuate the abilities of PCa cell proliferation, migration, and invasion by regulating the miR-9-5p/QKI-5 axis (Wu et al., 2019).Another study has also shown that MEG3 overexpression inhibits the viability, clonogenicity, invasion and migration of PC3 cells, as well as the tumorigenic effects of PC3 cells in mice (Zhou et al., 2020).More importantly, MEG3 has been found to be involved in the regulation of certain DNA repair genes.For instance, previous studies have reported that MEG3 impedes ovarian cancer cell proliferation by promoting the expression of the DNA repair gene PTEN (Wang et al., 2018).Additionally, it has been shown that MEG3 inhibits bladder cancer cell progression and tumor growth by promoting PTEN expression through sponging miR-494 (Shan et al., 2020).MEG3 suppresses the proliferation and metastasis of gastric cancer by increasing p53 transcription and expression, which helps protect the genome by coordinating various DNA damage response mechanisms (Wei & Wang, 2017).Furthermore, MEG3 expression is significantly upregulated after ischemia-reperfusion, leading to decreased intact PARP1 level and increased cleaved PARP1 level, thereby promoting cell apoptosis (Zou et al., 2019).These studies suggest that PARP-targeted CRPC therapies may require the activation of MEG3 to regulate DNA repair genes and exert anti-PCa effects.However, it is not clear whether PRAPi can affect the expression of MEG3 in PCa cells.
In this study, we confirmed that MEG3 was conspicuously downregulated in PCa patients and cell lines.Furthermore, we found that MEG3 was upregulated in PCa cells after PARPi (niraparib) treatment, which may be associated with PARPi-mediated anti-PCa effect.Therefore, we further investigated the downstream pathways regulated by niraparib/MEG3 in PCa.This study aimed to investigate the transcriptional regulation mechanisms related to PARPi in PCa.

Clinical specimens
PCa patients (n = 20, average age =51.4 ± 8.6 years) were recruited from Shaanxi Provincial People's Hospital.The inclusion criteria are listed below: (a) PCa diagnosis was confirmed by pathological investigations; (b) availability of comprehensive clinical information and tissue samples for experimental use; and (c) no prior administration of anti-tumor medications or treatments.Patients with other prostatic diseases, other malignant tumors, and severe complicated diseases of heart, lung, kidney and other organs or severe infectious diseases or received any anti-tumor treatment were excluded.PCa tissues and adjacent non-tumor tissues were excised from the patients during survey.All collected tissues were immediately frozen in liquid nitrogen and stored at −80 • C until further use.All samples obtained in this study were approved by the ethics committee of Shaanxi Provincial People's Hospital and abided by the ethical guidelines of the Declaration of Helsinki, and ethics committee agreed to waive informed consent.

Co-expression network analysis
The interactions between MEG3 and miRNAs, as well as miRNAs and mRNAs were predicted using TargetScan, miRTarBase and miRDB databases.The predicted target genes were compared with the dataset, and intersection of differentially expressed miRNAs and mRNAs was obtained to identify candidate target genes.Based on the regulatory relationships among MEG3, miRNAs and mRNAs, the MEG3-miRNA-mRNA regulatory network was established.The co-expression network charts were visualized and analyzed using Cytoscape 3.5.1 software.

CCK-8 assay
Cell counting kit 8 (CCK-8) assay was employed to evaluate cell proliferation.After transfection and niraparib treatment, PC3 cells suspended in RPMI-1640 medium (100 µL/well) were seeded in a 96-well plate (5×10 3 /well).Cells were then cultured for 0, 24, 48 and 72 h respectively before adding 10 µL of 100 nmol/L CCK-8 (C0040; Beyotime, Jiangsu, China) solution into the culture medium in each well.After 2 h of incubation, the 96-well plate was put into the microplate reader (iMark; Bio-Rad, Hercules, CA, USA), and the corresponding wavelength (450 nm) and measurement mode were selected.The measurement operation was performed and the absorbance value were recorded.

Cell migration assay
After transfection and niraparib treatment, PC3 cells were seeded in a 6-well plate.On the back of the 6-well plate, uniform horizontal lines were drawn with a marker pen at approximately 0.5-1 cm intervals.At least five lines were passed through each well.The cells were then incubated in 5% CO 2 at 37 • C until confluence reached 60-70%.Next, the cell surface was gently scratched using a sterile micropipette tip, and the detached cells were removed through PBS flushing.Afterwards, serum-free medium was added into plates and cultured for 24 h.The scratch area was monitored under a light microscope (Nikon, Japan) at different intervals (0 and 24 h), and analyzed by ImageJ 1.8.0 software (National Institutes of Health, Bethesda, MD, USA).Briefly, the image was imported into the software, and the following steps were applied successively: ''Enhance Constraint (Normalize, Saturated pixels: 0.3%)'', ''Smooth'', ''Find Edges'', ''Adjust (Threshold 0-20)'', and ''Analyze-Measure'' to obtain the scratch area.The percentage of cell migration was calculated by the formula: cell migration (%) = (the scratch area at 0 h the scratch area at 24 h)/the scratch area at 0 h ×100%.

Transwell invasion assay
Cell invasion was detected according to the reported method (Pang et al., 2021).Transwell chamber (8 µm pore size; CLS3422; Corning, NY, USA) precoated with 50 µL Matrigel (2 mg/mL) were used in Transwell invasion assay.The transfected PC3 cells suspended in FBS-free DMEM were seeded in the upper chamber, followed by addition of DMEM containing 10% FBS into the lower chamber.After 24 h culture at 37 • C, the invading cells in the lower chamber were stained by 0.1% crystal violet, and then observed under a light microscope (E100; Nikon, Toyko, Japan).The images of cells were analyzed using ImageJ 1.8.0 software (National Institutes of Health, Bethesda, MD, USA).The image was imported into the software, and the following steps were applied successively: ''Image'', ''Type'', and ''8-bit'' to convert the image to a grayscale image, ''Edit-Invert'' to convert the image background to black, ''Image-Adjust-Threshold'' with ''B&W'' selected to adjust the scroll bar and remove impurities from the background, and finally ''Analyze-Analyze Particles'' to obtain the analysis result, where the count represents the number of migrated cells.

Dual-luciferase reporter assay
The binding sites of miR-181-5p in MEG3 and GATA6 were searched in the Starbase v3.0 software (http://starbase.sysu.edu.cn/) in reference to the reported method (Yang et al., 2011).We clicked the item of miRNA target and chose miRNA-lncRNA/miRNA-mRNA, and entered miR-181-5p in the miRNA item, and all lncRNAs/mRNAs have potential binding relationship with miR-181-5p will appear.Subsequently, we searched for MEG3/GATA6 to identifu the corresponding binding sites.For dual-luciferase reporter assay, the 3 UTR sequence of the predicted target lncRNA/mRNA was inserted into the 3 UTR of the firefly luciferase vector.Then the constructed vector was co-transfected with miRNA into cells.If miRNA can bind to the inserted 3 UTR sequence of lncRNA/mRNA, the translation of firefly luciferase is inhibited, resulting in a decrease in fluorescence intensity.Renilla luciferase was used as an internal reference.The relative luciferase activity was determined by calculating the ratio of fluorescence values between firefly luciferase and renilla luciferase.The MEG3-wild type (MEG3-WT; 5 -AGU GAG UAA UGG UAG UGA AUG UU-3 ), MEG3 mutant type (MEG3-MUT; 5 -AGU GAG UAA UGG UAG CCC CCA AU-3 ), GATA6-WT (5 -CAG CAU UUU UUA UAA UGA AUG UA-3 ) and GATA6-MUT (5 -CAG CAU UUU UUA UAA AAC CCC CA-3 ) reporter vectors were constructed by Transgen Biotech (Beijing, China).The fragments of MEG3 or GATA6 containing the wild or mutated miR-181-5p binding site were synthesized and cloned into pmirGLO vector (E1330; Promega, Madison, WI, USA).Next, these plasmids were co-transfected into PC3 cells with NC mimic or miR-2113 mimic using Lipofectamine 3000 reagent for 48 h at 37 • C. The relative luciferase activity was tested with a Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA).

Animal studies
A total of 32 healthy male BALB/c nude mice (20 ± 2 g) were provided by the experimental animal center of Xi'an Jiaotong University.Animal experiments were approved and supervised by the Animal Ethics Committee of Shaanxi Provincial People's Hospital.All methods were carried out in accordance with relevant guidelines and regulations.Mice were maintained in cages under a standard experiment environment (12 h light/dark cycle, 22−25 • C temperature, 55-60% humidity) with free access to standard food and water.Mice were randomly divided into four groups based on the random number table method: PBS, Niraparib, Niraparib+sh-NC, Niraparib+sh-MEG3 (n = 8 per group).After 7 days of acclimatization, PC3 cells suspended in PBS (1×10 6 , 200 µL) were subcutaneously injected into the left flanks of mice to establish a xenograft tumor model.For niraparib treatment, niraparib (50 mg/kg) was diluted in 1×PBS (200 µL) and administered intraperitoneally into mice five days per week for four weeks.The same volume of 1×PBS was used as control.For Niraparib+sh-NC and Niraparib+sh-MEG3 groups, PC3 cells transfected with the negative control sh-NC or sh-CENPA were injected into mice, followed by niraparib treatment.All mice were carefully nursed after treatment.Afterwards, we measured the length and width of tumors every 7 days, and tumor volume was calculated by the formula: volume = [length × widt h 2 ]/2.After 28 days, mice were euthanized with an intraperitoneal injection of 100 mg/kg pentobarbital sodium, and tumors were excised, imaged by a camera (Z5; Nikon, Japan), and weighed.The measurement of tumor volume and weight was conducted by 2 independent researchers who were blinded to the experimental groups.

Statistical analysis
Experimental data from at least three independent experiments were presented as mean ± standard deviation (SD).The cell sample size is N = 6, and the animal sample size is N = 8.SPSS 22.0 software was used for Statistical analysis.The normal distribution of data was verified by the Shapiro-Wilk test, and the homogeneity of variances was verified by the Levene's test.Student's t test was used for comparations between two groups, and one-way analysis of variance (ANOVA) followed by Tukey-Kramer correction was used for comparations among multiple groups.Non-parametric tests (Kruskal-Wallis test/Mann-Whitney test) were used if data were not normally distributed or variances were not homogeneous.P < 0.05 was considered statistically significant.

The intimate relationship between LncRNA MEG3/miR-181-5p/GATA6 in PCa
First, we accessed the expression of MEG3 in tumor tissues of PCa patients using RT-qPCR.The results illustrated that MEG3 was dramatically downregulated in tumor tissues compared with non-tumor tissues (Fig. 1A).Then, we found that the MEG3/miR-181-5p/GATA binding protein 6 (GATA6) axis was intimately related in PCa by Co-expression network analysis (Fig. 1B).Additionally, our results indicated a significant upregulation of miR-181a-5p (Fig. 1C) and downregulation of GATA6 mRNA (Fig. 1D) in tumor tissues of PCa patients.As expected, MEG3 expression showed a negative correlation with miR-181-5p expression (Fig. 1E), and miR-181-5p expression showed a negative correlation with GATA6 mRNA (Fig. 1F) in our recruited PCa patients.

Niraparib treatment upregulated MEG3 and GATA6, and downregulated miR-181-5p expression in PCa cells
PARPi exert their effects by exploiting synthetic lethality in cancer cells with defects in homologous recombination repair genes, such as BRAC, thereby inhibiting DNA damage repair and promoting apoptosis in cancer cells (Slade, 2020;Li et al., 2020).It was reported that niraparib showed impressive performance in phase II trials for mCRPC patients (Flippot et al., 2022).Recent studies have suggested that PARPi therapy may exert anti-PCa effects through activating MEG3 and thereby promoting PARP cleavage (Wang et al., 2018;Shan et al., 2020;Zou et al., 2019).Thus, we explored whether the anti-PCa effect of niraparib is related to the change of MEG3 expression.We first treated PC3 cells with different concentrations of niraparib.CCK-8 assay showed that niraparib treatment restrained PC3 cell proliferation in a dose dependent manner, and 4 µM and 8 µM niraparib had comparable inhibitory activity against PCa cell proliferation (Fig. 2A).Then, we treated PC3 cells with niraparib for 0, 30, 60, 120 min.It was observed that niraparib-mediated PC3 cell proliferation inhibition effect enhanced with incubation time (Fig. 2B).Next, we investigated the effect of niraparib on MEG3 expression in PC3 cells.RT-qPCR results revealed that niraparib treatment substantially upregulated MEG3 expression in a dose dependent manner, and which reached peak value at 4 µM (Fig. 2C).Moreover, the promoting effect of niraparib on MEG3 expression intensified with incubation time, and which reached peak value at 120 min (Fig. 2D).Besides, we also found that niraparib treatment downregulated miR-181-5p expression (Figs. 2E, 2F).and upregulated GATA6 mRNA expression (Figs. 2G, 2H).These findings suggest that the anti-PCa effects of niraparib may be mediated through the MEG3/miR-181-5p/GATA6 axis.

DISCUSSION
The development of PARPi therapy has prominently improved the treatment outcomes of metastatic PCa patients with certain genetic mutations (Grewal, Grewal & Tabbara, 2021).
It was reported that niraparib and talazoparib showed impressive performance in phase II trials for mCRPC patients (Flippot et al., 2022).A phase 2 clinical trial demonstrated that niraparib is relatively safe and exhibits anti-tumor activity in patients with mCRPC (Smith et al., 2022).Moreover, a recent study has illustrated that niraparib offers better tissue exposure and more potent tumor growth suppression in PCa bone metastasis mice compared to other PARPi (Snyder et al., 2022).In our study, we investigated the molecular mechanisms underlying the anti-PCa effect of niraparib.Current evidence suggests that lncRNA MEG3 is downregulated in PCa tissues.MEG3 overexpression has been shown to mitigate PCa cell proliferation and metastasis, induce apoptosis, and attenuate tumor development in mice (Wu et al., 2019;Zhou et al., 2020).Notably, MEG3 has been found to be involved in the progression of multiple cancers through regulating some DNA repair genes, such as PTEN (Wang et al., 2018;Shan et al., 2020) and p53 (Wei & Wang, 2017).Importantly, it has also been found that MEG3 overexpression decreases intact PARP level and increases cleaved PARP level, thus promoting cell apoptosis (Zou et al., 2019).Based on these findings, we hypothesized that PARPi therapy may require the activation of MEG3 to regulate DNA repair gene and exert anti-PCA effects.The effect of PRAPi on MEG3 expression has not been studied to date.Therefore, to explore more targets for PRAPi therapy, it is of great significance to investigate the impact of MEG3 expression on PARP1 targeted CRPC treatment.As expected, our results showed that niraparib treatment upregulated MEG3 expression in PCa cells.Additionally, niraparib administration restrained tumor growth in a PCa xenograft mouse model, while MEG3 silencing treatment retarded these effects.Thus, niraparib mediated-MEG3 upregulation is a crucial mechanism for tumor inhibition.
Our study identified miR-181-5p as a highly expressed miRNA in PCa that is negatively correlated with MEG3 expression.A previous miRNA-microarray analysis identified that miR-181-5p was associated with drug resistance and efflux, and epithelial to mesenchymal transition in PCa (Verma et al., 2019).It has also been shown that miR-181-5p can lead to cisplatin resistance in PCa cells through complementary interactions with the 3 UTR of the proapoptotic protein BAX transcript (Cai et al., 2017).Moreover, MiR-181 has been found to facilitate PCa cell proliferation and tumor development in mice through regulation of DAX1, an androgen receptor negative regulator (Tong et al., 2014).These findings indicate that miR-181-5p is closely related to the natural course, drug resistance, and androgen receptor resistance of PCa.Our study implied that miR-181a-5p was obviously upregulated in PCa patients, and its expression was negatively correlated with MEG3 expression.Subsequently, we confirmed miR-181a-5p as a target of MEG3 in PCa cells through Starbase database prediction and dual-luciferase reporter assay validation.Rescue experiments implicated that miR-181a-5p overexpression reversed MEG3 overexpressionmediated suppression of PCa cell proliferation and metastasis, implying that MEG3 exerted anti-PCa effect through reducing miR-181-5p expression.
Our study found that an intimate relationship between the MEG3/miR-181-5p/GATA6 axis in PCa.GATA6 is a member of the gene family with the promoter GATA core conserved sequence.An RNA-sequence analysis of tumor tissue samples from PCa patients revealed that GAGT6 is a downregulated gene in PCa (Nikitina et al., 2017).Moreover, lncRNA LINC00261 has been shown to intensify GATA6-mediated transcriptional inhibition and suppress PCa tumorigenesis (Li, Li & Wei, 2020).GATA6 has been identified as a downstream of the Linc00518/miR-216b-5p axis, and is closely related to paclitaxel resistance in PCa (He et al., 2019).Our further study confirmed that GATA6 mRNA was downregulated in PCa patients.GATA6 was a target gene of miR-181-5p, and its expression was suppressed by miR-181-5p.Furthermore, miR-181-5p inhibition restrained PCa cell proliferation, migration, and invasion, whereas these effects were abrogated by GATA6 silencing.Therefore, we proposed that MEG3 participated in PCa progression through the miR-181-5p/GATA6 pathway.

CONCLUSIONS
PARPi have been approved for the treatment of PCa patients in the CRPC stage.Our study illustrated that the representative PRAPi drug niraparib, restrained PCa cell proliferation, migration and invasion and delayed tumor growth in mice by regulating the MEG3/miR-181-5p/GATA6 pathway.These findings reveal a novel molecular mechanism by which niraparib exerts its anti-PCa effects.